超越「完全手术切除」与「满意减瘤」:低体积残留病灶可否作为初次减瘤手术的另一选择
回顾性分析2010年1月至2014年11月接受初次减瘤手术的240例FIGO IIIC/IV期上皮性卵巢/输卵管/原发性腹膜癌患者,按残留病灶体积分组比较生存。完全切除者94例(39.2%),残留≤1 cm且局限于单个解剖部位者41例(17.1%),残留≤1 cm但位于多个解剖部位者67例(27.9%),减瘤不满意者38例(15.8%)。完全切除与≤1 cm单部位者预后最好,≤1 cm多部位者生存与减瘤不满意者相似。
要点
- 完全切除者中位无进展生存23个月,残留≤1 cm单部位者19个月,多部位者13个月,减瘤不满意者10个月。
- 完全切除者中位总生存未达到,残留≤1 cm单部位者64个月,多部位者50个月,减瘤不满意者49个月。
- 残留≤1 cm但位于多个解剖部位者虽被视为满意减瘤,生存与减瘤不满意者相似。
核心结论
- 初次减瘤手术后,完全切除与残留≤1 cm且局限于单个解剖部位者预后最好。
- 残留≤1 cm但位于多个解剖部位者虽被视为满意减瘤,生存与减瘤不满意者相似。
研究设计与样本
- 回顾性分析2010年1月至2014年11月接受初次减瘤手术的FIGO IIIC和IV期上皮性卵巢/输卵管/原发性腹膜癌患者病历。
- 共240例患者接受初次减瘤手术,收集人口学、手术特征、残留病灶、残留病灶解剖部位及结局数据。
- 在未完全切除但残留≤1 cm者中,以残留病灶累及的解剖部位数(单部位 vs 多部位)作为残留病灶体积的替代指标。
- 评估残留病灶体积对无进展生存和总生存的影响。
主要发现
- 240例中,完全切除94例(39.2%),残留≤1 cm且局限于单个解剖部位41例(17.1%),残留≤1 cm但位于多个解剖部位67例(27.9%),减瘤不满意38例(15.8%)。
- 完全切除、残留≤1 cm单部位、残留≤1 cm多部位、减瘤不满意者的中位无进展生存分别为23、19、13、10个月(p < 0.001)。
- 完全切除、残留≤1 cm单部位、残留≤1 cm多部位、减瘤不满意者的中位总生存分别为未达到、64、50、49个月(p = 0.001)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To examine the relationship between volume of residual disease and oncologic outcomes among patients with advanced-stage epithelial ovarian/fallopian tube/primary peritoneal carcinoma undergoing primary debulking surgery (PDS). For patients that did not undergo a complete surgical resection (CSR), a surrogate for volume of residual disease was used to assess oncologic outcomes. METHODS: Medical records of patients with FIGO stage IIIC and IV epithelial ovarian/fallopian tube/primary peritoneal carcinoma undergoing PDS between January 2010 and November 2014 were reviewed. Patient demographics, operative characteristics, residual disease, anatomic site of residual disease and outcome data were collected. Among patients who did not undergo CSR, but had ≤1 cm of residual disease, the number of anatomic sites (single location vs. multiple locations) with residual disease was utilized as a surrogate for volume of residual disease. The effect of residual disease volume on progression-free survival (PFS) and overall survival (OS) was evaluated. RESULTS: Of 240 patients undergoing PDS, 94 (39.2%) had CSR, 41 (17.1%) had ≤1 cm of residual disease confined to a single anatomic location (≤1 cm-SL), 67 (27.9%) had ≤1 cm of residual disease in multiple anatomic locations (≤1 cm-ML) and 38 (15.8%) were sub-optimally (SO) debulked. Median PFS for CSR, ≤1 cm-SL, ≤1 cm-ML and SO-debulked were: 23, 19, 13 and 10 months, respectively (p < 0.001). Median OS for CSR, ≤1 cm-SL, ≤1 cm-ML and SO-debulked were: Not yet reached, 64, 50 and 49 months, respectively (p = 0.001). CONCLUSIONS: Following PDS, CSR and ≤ 1 cm-SL patients have the best prognosis. In contrast, despite being considered "optimally debulked", ≤1 cm-ML patients have survival similar to those SO-debulked.
引用
- Manning-Geist BL, Hicks-Courant K, Gockley AA, et al. Moving beyond "complete surgical resection" and "optimal": Is low-volume residual disease another option for primary debulking surgery? Gynecol Oncol. 2018. PMID: 29933927. doi:10.1016/j.ygyno.2018.06.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。